Study finds use of two blood thinners can increase the bleeding risk significantly in patients
A daily blood thinner like aspirin is a commonly used, generally safe therapy for people who need help preventing heart attacks or stroke.
But new Michigan Medicine research finds more reason to reconsider aspirin use when a patient is also taking an anticoagulant.
The study, just published in JAMA Internal Medicine, reveals a significant increase in adverse outcomes for people taking both aspirin and warfarin, a long-popular anticoagulant. It is often prescribed for stroke prevention in patients with atrial fibrillation and venous thromboembolic disease. Both groups of people need to avoid developing blood clots that could lead to stroke or pulmonary embolism.
“Nearly 2,500 patients who were prescribed warfarin were taking aspirin without any clear reason, over a seven-year period,” says senior author Geoffrey Barnes, M.D., M.Sc., a vascular cardiologist at the University of Michigan Frankel Cardiovascular Center and an assistant professor of internal medicine at the U-M Medical School. “No doctors really own the prescribing of aspirin, so it’s possible it got overlooked.”
Some patients could have been taking aspirin already when they began anticoagulation with warfarin for a new issue like Afib or VTE, and they didn’t stop the aspirin. Others may have started aspirin for other reasons while already taking warfarin, which is easy to do because it’s over the counter, researchers say.
“For the patients who are on both therapies, clinicians should review their medical history to determine if it’s really necessary to be on both drugs.”
More bleeding without more benefit
In this study, 5.7 percent of those using combination therapy experienced major bleeding events after one year, compared to 3.3 percent of those on warfarin only. The combination group that was using aspirin without a clear indication also visited the emergency department and/or were hospitalized for bleeding significantly more often.
Yet, there wasn’t a difference in stroke or heart attack outcomes that are typical uses for aspirin, Barnes says. The mortality rates at one year were similar between both groups, and 2.3 percent of those on both medications had a thrombotic event at one year compared to 2.7 percent of those on warfarin alone. The study cohort included 6,539 patients who were enrolled at six anticoagulation clinics in Michigan between 2010 and 2017.
“Clinicians should ask their patients who are anticoagulated with warfarin if they’re taking aspirin as well,” says first author Jordan Schaefer, M.D., a hematologist at Michigan Medicine and assistant professor of internal medicine. “For the patients who are on both therapies, clinicians should review their medical history to determine if it’s really necessary to be on both drugs.”
Although 37.5 percent of the patients in this study were receiving combination warfarin and aspirin therapy without a clear indication, the combination does make sense for a small number of people. Barnes says patients who may need to be on both medications include those who have had a recent heart attack, recent coronary stent placement or bypass surgery, prior mechanical valve surgery, or known peripheral artery disease.
